15 analysts have expressed a variety of opinions on Sarepta Therapeutics SRPT over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 7 | 0 | 0 | 3 |
| Last 30D | 0 | 0 | 0 | 0 | 1 |
| 1M Ago | 1 | 1 | 0 | 0 | 2 |
| 2M Ago | 3 | 4 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Analysts have recently evaluated Sarepta Therapeutics and provided 12-month price targets. The average target is $158.87, accompanied by a high estimate of $205.00 and a low estimate of $75.00. This current average has decreased by 5.25% from the previous average price target of $167.67.
Deciphering Analyst Ratings: An In-Depth Analysis
The perception of Sarepta Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Mitchell Kapoor | HC Wainwright & Co. | Maintains | Sell | $75.00 | $75.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Lowers | Sell | $75.00 | $80.00 |
| Biren Amin | Piper Sandler | Lowers | Overweight | $182.00 | $200.00 |
| Gil Blum | Needham | Lowers | Buy | $202.00 | $205.00 |
| Mitchell Kapoor | HC Wainwright & Co. | Announces | Sell | $80.00 | - |
| Whitney Ijem | Guggenheim | Raises | Buy | $150.00 | $148.00 |
| Brian Skorney | Baird | Lowers | Outperform | $193.00 | $200.00 |
| Kristen Kluska | Cantor Fitzgerald | Raises | Overweight | $167.00 | $152.00 |
| Gavin Clark-Gartner | Evercore ISI Group | Lowers | Outperform | $170.00 | $179.00 |
| Gil Blum | Needham | Maintains | Buy | $205.00 | $205.00 |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $182.00 | $182.00 |
| Andrew Tsai | Jefferies | Announces | Buy | $165.00 | - |
| Gil Blum | Needham | Maintains | Buy | $205.00 | $205.00 |
| Danielle Brill | Raymond James | Announces | Outperform | $150.00 | - |
| Brian Abrahams | RBC Capital | Raises | Outperform | $182.00 | $181.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Sarepta Therapeutics. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Sarepta Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Sarepta Therapeutics analyst ratings.
All You Need to Know About Sarepta Therapeutics
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
A Deep Dive into Sarepta Therapeutics's Financials
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Sarepta Therapeutics's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 40.79%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Sarepta Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 7.19%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Sarepta Therapeutics's ROE excels beyond industry benchmarks, reaching 2.93%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.96%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.14.
Understanding the Relevance of Analyst Ratings
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
